[1]
Elder DE,Bastian BC,Cree IA,Massi D,Scolyer RA, The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. Archives of pathology & laboratory medicine. 2020 Apr [PubMed PMID: 32057276]
[2]
Abbasi NR,Shaw HM,Rigel DS,Friedman RJ,McCarthy WH,Osman I,Kopf AW,Polsky D, Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004 Dec 8 [PubMed PMID: 15585738]
[3]
Coit DG,Thompson JA,Albertini MR,Barker C,Carson WE,Contreras C,Daniels GA,DiMaio D,Fields RC,Fleming MD,Freeman M,Galan A,Gastman B,Guild V,Johnson D,Joseph RW,Lange JR,Nath S,Olszanski AJ,Ott P,Gupta AP,Ross MI,Salama AK,Skitzki J,Sosman J,Swetter SM,Tanabe KK,Wuthrick E,McMillian NR,Engh AM, Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2019 Apr 1 [PubMed PMID: 30959471]
[4]
Schüle SC,Eigentler TK,Garbe C,la Fougère C,Nikolaou K,Pfannenberg C, Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. European journal of nuclear medicine and molecular imaging. 2016 Mar [PubMed PMID: 26384681]
[5]
Long GV,Menzies AM,Nagrial AM,Haydu LE,Hamilton AL,Mann GJ,Hughes TM,Thompson JF,Scolyer RA,Kefford RF, Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Apr 1 [PubMed PMID: 21343559]
[6]
Hodi FS,O'Day SJ,McDermott DF,Weber RW,Sosman JA,Haanen JB,Gonzalez R,Robert C,Schadendorf D,Hassel JC,Akerley W,van den Eertwegh AJ,Lutzky J,Lorigan P,Vaubel JM,Linette GP,Hogg D,Ottensmeier CH,Lebbé C,Peschel C,Quirt I,Clark JI,Wolchok JD,Weber JS,Tian J,Yellin MJ,Nichol GM,Hoos A,Urba WJ, Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010 Aug 19 [PubMed PMID: 20525992]
[7]
Robert C,Thomas L,Bondarenko I,O'Day S,Weber J,Garbe C,Lebbe C,Baurain JF,Testori A,Grob JJ,Davidson N,Richards J,Maio M,Hauschild A,Miller WH Jr,Gascon P,Lotem M,Harmankaya K,Ibrahim R,Francis S,Chen TT,Humphrey R,Hoos A,Wolchok JD, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England journal of medicine. 2011 Jun 30 [PubMed PMID: 21639810]
[8]
Weber J,Mandala M,Del Vecchio M,Gogas HJ,Arance AM,Cowey CL,Dalle S,Schenker M,Chiarion-Sileni V,Marquez-Rodas I,Grob JJ,Butler MO,Middleton MR,Maio M,Atkinson V,Queirolo P,Gonzalez R,Kudchadkar RR,Smylie M,Meyer N,Mortier L,Atkins MB,Long GV,Bhatia S,Lebbé C,Rutkowski P,Yokota K,Yamazaki N,Kim TM,de Pril V,Sabater J,Qureshi A,Larkin J,Ascierto PA, Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. The New England journal of medicine. 2017 Nov 9 [PubMed PMID: 28891423]
[9]
Eggermont AMM,Blank CU,Mandala M,Long GV,Atkinson V,Dalle S,Haydon A,Lichinitser M,Khattak A,Carlino MS,Sandhu S,Larkin J,Puig S,Ascierto PA,Rutkowski P,Schadendorf D,Koornstra R,Hernandez-Aya L,Maio M,van den Eertwegh AJM,Grob JJ,Gutzmer R,Jamal R,Lorigan P,Ibrahim N,Marreaud S,van Akkooi ACJ,Suciu S,Robert C, Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. The New England journal of medicine. 2018 May 10 [PubMed PMID: 29658430]
[10]
Long GV,Stroyakovskiy D,Gogas H,Levchenko E,de Braud F,Larkin J,Garbe C,Jouary T,Hauschild A,Grob JJ,Chiarion-Sileni V,Lebbe C,Mandalà M,Millward M,Arance A,Bondarenko I,Haanen JB,Hansson J,Utikal J,Ferraresi V,Kovalenko N,Mohr P,Probachai V,Schadendorf D,Nathan P,Robert C,Ribas A,DeMarini DJ,Irani JG,Swann S,Legos JJ,Jin F,Mookerjee B,Flaherty K, Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (London, England). 2015 Aug 1 [PubMed PMID: 26037941]
[11]
Robert C,Karaszewska B,Schachter J,Rutkowski P,Mackiewicz A,Stroiakovski D,Lichinitser M,Dummer R,Grange F,Mortier L,Chiarion-Sileni V,Drucis K,Krajsova I,Hauschild A,Lorigan P,Wolter P,Long GV,Flaherty K,Nathan P,Ribas A,Martin AM,Sun P,Crist W,Legos J,Rubin SD,Little SM,Schadendorf D, Improved overall survival in melanoma with combined dabrafenib and trametinib. The New England journal of medicine. 2015 Jan 1 [PubMed PMID: 25399551]
[12]
Larkin J,Ascierto PA,Dréno B,Atkinson V,Liszkay G,Maio M,Mandalà M,Demidov L,Stroyakovskiy D,Thomas L,de la Cruz-Merino L,Dutriaux C,Garbe C,Sovak MA,Chang I,Choong N,Hack SP,McArthur GA,Ribas A, Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. The New England journal of medicine. 2014 Nov 13 [PubMed PMID: 25265494]
[13]
Ascierto PA,McArthur GA,Dréno B,Atkinson V,Liszkay G,Di Giacomo AM,Mandalà M,Demidov L,Stroyakovskiy D,Thomas L,de la Cruz-Merino L,Dutriaux C,Garbe C,Yan Y,Wongchenko M,Chang I,Hsu JJ,Koralek DO,Rooney I,Ribas A,Larkin J, Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. The Lancet. Oncology. 2016 Sep [PubMed PMID: 27480103]
[14]
Long GV,Flaherty KT,Stroyakovskiy D,Gogas H,Levchenko E,de Braud F,Larkin J,Garbe C,Jouary T,Hauschild A,Chiarion-Sileni V,Lebbe C,Mandalà M,Millward M,Arance A,Bondarenko I,Haanen JBAG,Hansson J,Utikal J,Ferraresi V,Mohr P,Probachai V,Schadendorf D,Nathan P,Robert C,Ribas A,Davies MA,Lane SR,Legos JJ,Mookerjee B,Grob JJ, Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Jul 1 [PubMed PMID: 28475671]
[15]
Dréno B,Ribas A,Larkin J,Ascierto PA,Hauschild A,Thomas L,Grob JJ,Koralek DO,Rooney I,Hsu JJ,McKenna EF,McArthur GA, Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 May 1 [PubMed PMID: 28444112]
[16]
Dummer R,Ascierto PA,Gogas HJ,Arance A,Mandala M,Liszkay G,Garbe C,Schadendorf D,Krajsova I,Gutzmer R,Chiarion-Sileni V,Dutriaux C,de Groot JWB,Yamazaki N,Loquai C,Moutouh-de Parseval LA,Pickard MD,Sandor V,Robert C,Flaherty KT, Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. The Lancet. Oncology. 2018 May [PubMed PMID: 29573941]
[17]
Dummer R,Ascierto PA,Gogas HJ,Arance A,Mandala M,Liszkay G,Garbe C,Schadendorf D,Krajsova I,Gutzmer R,Chiarion Sileni V,Dutriaux C,de Groot JWB,Yamazaki N,Loquai C,Moutouh-de Parseval LA,Pickard MD,Sandor V,Robert C,Flaherty KT, Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. 2018 Oct [PubMed PMID: 30219628]
[18]
Anker CJ,Grossmann KF,Atkins MB,Suneja G,Tarhini AA,Kirkwood JM, Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). International journal of radiation oncology, biology, physics. 2016 Jun 1 [PubMed PMID: 27131079]
[19]
Gershenwald JE,Scolyer RA,Hess KR,Sondak VK,Long GV,Ross MI,Lazar AJ,Faries MB,Kirkwood JM,McArthur GA,Haydu LE,Eggermont AMM,Flaherty KT,Balch CM,Thompson JF, Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: a cancer journal for clinicians. 2017 Nov [PubMed PMID: 29028110]